Sitagliptin

This classification denotes a protease inhibitor with the molecular formula C16H15F6N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) QFP0P1DV7Z, chemically known as 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine phosphate but more generally known as sitagliptin, which bears US NIH Compound Identifier 6451150. European Medicines Agency schedules Sitagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25227 WHO schedules sitagliptin in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule sitagliptin under HS 29335990 and SITC 51576. As of Q4 2014, SITAGLIPTIN remains US FDA's Preferred Term for this commodity. Sitagliptin bears US NLM identifiers UMLS ID C1565750 and NCI Concept Code C73838. SMILES: P(=O)(O)(O)O.FC(F)(F)C1N2CCN(CC2NN1)C(=O)CC(N)CC1C(F)CC(F)C(F)C1.